For example, the JAK2/STAT3 inhibitor, WP1066, which we previously investigated in BTSC orthotopic xenograft models,17 and found here to be synergistic with afatinib, is especially promising and was recently granted approval by the FDA for GBM as an orphan drug. This evidence concerns the gene JAK2 and glioblastoma.